Compare Davita Inc (DVA) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Okta, Inc. — how do they compare? Davita Inc trades at $229.45 (market cap $14.92B), while Okta, Inc. trades at $150.24 (market cap $26.87B). The key difference: Okta, Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| DVA | OKTA | |
|---|---|---|
Market Cap | $14.92B | $26.87B |
Sector | Health | Technology |
52-Week High | $235.71 | $154.62 |
52-Week Low | $103.87 | $62.93 |
Enterprise Value | $27.47B | $24.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
OKTA trades at $139.53, up 0.65% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding the $0.853 estimate. Revenue grew to $2.61 billion in 2025, and net income turned positive at $28 million. Analyst sentiment is positive, with 72.55% recommending Buy.
The outlook is favorable due to AI-driven demand for cybersecurity, but high valuation multiples pose risks. The stock faces competition and must sustain growth to justify its P/E of 101.11. Upside exists if earnings continue to beat expectations, yet volatility from market sentiment shifts is a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
